Of women aged 40 years or older without breast cancer, 3% carry pathogenic variants in breast cancer risk genes — including many with no red flags in their family history.

Three oncology organizations weigh in on the CMS Medicare Physician Fee Schedule final rule for 2026, highlighting key pros ...

Postpartum use of domperidone to increase milk production in breastfeeding is not correlated with increased mental ...

The combination of gastric electrical stimulation and pyloroplasty produces better outcomes than pyloroplasty alone in ...

Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.

The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.

The EMA concluded that Melatomed’s benefits outweigh its risks and supported granting marketing authorizations in Germany, Austria, Denmark, and Sweden.

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...

AFSOS 2025 introduced the first European reference for photobiomodulation, outlining the evidence, dosing, and clinical use in supportive cancer care.

The majority of knees without radiographic osteoarthritis experience an increase in structural damage over time, with the most frequent changes being observed in the patellofemoral joint.

The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...